{"filing":{"accession_number":"0001213900-26-058795","cik":"0001728328","ticker":null,"company_name":"InMed Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"ea0291482-8k425_inmed.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/ea0291482-8k425_inmed.htm"},"classifications":[{"id":227,"accession_number":"0001213900-26-058795","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"InMed Pharmaceuticals entered into a definitive merger agreement with Mentari Therapeutics on May 19, 2026, whereby Mentari shareholders will receive approximately 98.49% of the combined company post-closing. This is a material acquisition/change of control transaction requiring shareholder approval, Nasdaq listing approval, and SEC registration statement filing. The transaction contemplates a $125 million equity valuation for Mentari and involves a two-step merger structure with concurrent $150 million financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:23:09.175113+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":228,"accession_number":"0001213900-26-058795","item_number":"5.01","item_title":"Changes in Control of Registrant.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses a change in control of the registrant and incorporates Item 1.01 by reference. Item 1.01 covers entry into material acquisition, disposition, merger, or change of control transactions. A change in control is a material event that would significantly affect investor assessment of the registrant's ownership, governance, and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:23:09.175113+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":229,"accession_number":"0001213900-26-058795","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.35,"reasoning":"Item 5.02 is filed but contains only a cross-reference to Item 1.01 without disclosing specific details about any executive departure, appointment, or compensation arrangement. Without the actual content of Item 1.01, the materiality and specific event type cannot be determined. The filing appears incomplete or the substantive disclosure is located elsewhere in the 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:23:09.175113+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":230,"accession_number":"0001213900-26-058795","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses entry into a Merger Agreement between InMed Pharmaceuticals and Mentari, announced via joint press release on May 19, 2026. The disclosure explicitly references \"the entry into the Merger Agreement\" and describes the proposed merger's structure, timing, financing, and expected combined company operations. This constitutes a material acquisition/change of control event under Item 1.01 or 2.01, even though disclosed under Item 7.01 (Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:23:09.175113+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":null,"filing_date":"2026-05-19"}]}